


# Stabilis

Na Ca  
K Mg



## Sodium bicarbonate



Noms commerciaux

Bicarbonato de sodio	Chili, Colombie, Equateur, Mexique, Portugal
Debonal	Mexique
Natrium bicarbonat	Autriche, Suisse
Natrium Hydrogen Karbonat	Hongrie
Natrium Hydrogencarbonat	Allemagne
Sodio bicarbonato	Italie
Sodium bicarbonate	France, Maroc, Tunisie



### Stabilité des solutions

POF		4 mg/ml	21-24°C		48			3116
POF		4 >> 11,45 mg/ml	2-4°C		7			3116
POF		7,6 >> 11,45 mg/ml	21-24°C		30			3116
POF		0,336 mg/ml	25°C		48			4383
POF		12,6 mg/ml	-20°C		21			3329
POF		12,6 mg/ml	2-8°C		21			3329
POF		12,6 mg/ml	23-25°C		7			3329
POF		4 mg/ml	21-24°C		48			3116
POF		4 >> 11,45 mg/ml	2-4°C		7			3116
POF		7,6 >> 11,45 mg/ml	21-24°C		30			3116
POF		8,4 mg/ml	-20°C		21			3329
POF		8,4 mg/ml	2-8°C		21			3329
POF		8,4 mg/ml	23-25°C		7			3329



## Stabilité en mélange

		50 mg/ml	22°C		Cytarabine : 0,2 & 1 mg/ml	7		850
		50 mg/ml	8°C		Cytarabine : 0,2 & 1 mg/ml	7		850
		7,6 mg/ml	23°C		Lidocaine hydrochloride : 9,1 mg/ml	91		3263
		7,6 mg/ml	5°C		Lidocaine hydrochloride : 9,1 mg/ml	91		3263
		50 mg/ml	22°C		Cytarabine : 0,2 & 1 mg/ml	7		850
		50 mg/ml	8°C		Cytarabine : 0,2 & 1 mg/ml	7		850
		6 < pH < 9 mg/ml	25°C		Ixabepilone : 0,2 >> 0,6 mg/ml	6		3084
		0,42 mg/ml	- 20°C		Diclofenac : 0,75 mg/ml	60		3076
		0,42 mg/ml	2-8°C		Diclofenac : 0,75 mg/ml	30		3076
		6 < pH < 9 mg/ml	25°C		Ixabepilone : 0,2 >> 0,6 mg/ml	6		3084
		7,8 mg/ml	4-7°C		Lidocaine hydrochloride : 9 mg/ml Epinephrine hydrochloride : 9 µg/ml	7		2878
		7,8 mg/ml	4-7°C		Lidocaine hydrochloride : 18 mg/ml Epinephrine hydrochloride : 9 µg/ml	7		2878
		7,8 mg/ml	4-7°C		Lidocaine hydrochloride : 9 mg/ml	28		2878
		7,8 mg/ml	4-7°C		Lidocaine hydrochloride : 18 mg/ml	28		2878
		0,1 mg/ml	23°C		Artesunate : 0,6 mg/ml	10		2737
		0,1 mg/ml	36°C		Artesunate : 0,6 mg/ml	4		2737
		0,1 mg/ml	9°C		Artesunate : 0,6 mg/ml	60		2737



## Facteur influençant la stabilité

				3466
--	--	--	--	------



## Compatibilités

	Sodium bicarbonate : 42 mg/ml Aciclovir sodium : 5 mg/ml	336
	Sodium bicarbonate : 84 mg/ml Allopurinol sodium : 3 mg/ml	307
	Sodium bicarbonate : 84 mg/ml Amifostine : 10 mg/ml	3

		Sodium bicarbonate Amiodarone hydrochloride		3464
		Sodium bicarbonate : 8.4 mg/ml Amiodarone hydrochloride : 3 mg/ml		200
		Sodium bicarbonate : 3 mg/ml Amiodarone hydrochloride : 3 mg/ml		205
		Sodium bicarbonate Amiodarone hydrochloride		3466
		Sodium bicarbonate : 84 mg/ml Amiodarone hydrochloride : 6 mg/ml		1611
		Sodium bicarbonate : 84 mg/ml Amiodarone hydrochloride : 15 mg/ml		3212
		Sodium bicarbonate : 84 mg/ml Amiodarone hydrochloride : 15 mg/ml		3823
		Sodium bicarbonate Amoxicillin sodium / clavulanic acid		3545
		Sodium bicarbonate : 84 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
		Sodium bicarbonate : 84 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml		921
		Sodium bicarbonate : 84 mg/ml Anidulafungin : 0.5 mg/ml		1982
		Sodium bicarbonate : 14 mg/ml Asparaginase : 120 UI/ml		150
		Sodium bicarbonate Atracurium besylate		3629
		Sodium bicarbonate Atracurium besylate		3676
		Sodium bicarbonate : 84 mg/ml Aztreonam : 40 mg/ml		99
		Sodium bicarbonate : 84 mg/ml Bivalirudin : 5 mg/ml		1713
		Sodium bicarbonate : 84 mg/ml Caffeine : 10 mg/ml		3964
		Sodium bicarbonate Caffeine citrate : 20 mg/ml		3379
		Sodium bicarbonate Calcium gluconate		3644
		Sodium bicarbonate : 84 mg/ml Carmustine : 0,1 mg/ml		715
		Sodium bicarbonate : 84 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
		Sodium bicarbonate : 84 mg/ml Cefmetazole sodium : 100 mg/ml		93
		Sodium bicarbonate : 8,4 mg/ml Ceftaroline fosamil : 2,22 mg/ml	<b>RL</b>	3249
		Sodium bicarbonate : 8,4 mg/ml Ceftaroline fosamil : 2,22 mg/ml		3249
		Sodium bicarbonate Ceftazidime		3543
		Sodium bicarbonate Ceftazidime		3883

		Sodium bicarbonate : 84 mg/ml Ceftobiprole medocartil sodium : 2 mg/ml		2269
		Sodium bicarbonate : 84 mg/ml Ceftobiprole medocartil sodium : 2 mg/ml	RL	2269
		Sodium bicarbonate : 84 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Sodium bicarbonate : 14 mg/ml Ceftriaxone disodium : 100 mg/ml	∅	150
		Sodium bicarbonate : 8,4 >> 42 mg/ml Ciprofloxacin lactate : 1 mg/ml		14
		Sodium bicarbonate : 84 mg/ml Ciprofloxacin lactate : 2 mg/ml		288
		Sodium bicarbonate : 63 & 84 mg/ml Ciprofloxacin lactate : 1 mg/ml		14
		Sodium bicarbonate : 63 & 84 mg/ml Ciprofloxacin lactate : 2 mg/ml		14
		Sodium bicarbonate : 8,4 >> 84 mg/ml Ciprofloxacin lactate : 2 mg/ml		14
		Sodium bicarbonate : 84 mg/ml Ciprofloxacin lactate : 2 mg/ml		288
		Sodium bicarbonate : 0,84 mg/ml Ciprofloxacin lactate : 2 mg/ml		289
		Sodium bicarbonate : 8,4 >> 42 mg/ml Ciprofloxacin lactate : 1 mg/ml		14
		Sodium bicarbonate : 63 & 84 mg/ml Ciprofloxacin lactate : 1 mg/ml		14
		Sodium bicarbonate : 4 mg/ml Ciprofloxacin lactate : 2 mg/ml		285
		Sodium bicarbonate : 8.4 mg/ml Ciprofloxacin lactate : 10 mg/ml		269
		Sodium bicarbonate : 84 mg/ml Ciprofloxacin lactate : 10 mg/ml		269
		Sodium bicarbonate : 8,4 >> 42 mg/ml Ciprofloxacin lactate : 2 mg/ml		14
		Sodium bicarbonate : 84 mg/ml Cisatracurium besylate : 2 mg/ml		299
		Sodium bicarbonate : 84 mg/ml Cisatracurium besylate : 5 mg/ml		299
		Sodium bicarbonate Cisatracurium besylate		3601
		Sodium bicarbonate : 84 mg/ml Cisatracurium besylate : 0.1 mg/ml		299
		Sodium bicarbonate : 84 mg/ml Cisatracurium besylate : 5 mg/ml	∅	3212
		Sodium bicarbonate Cisatracurium besylate		3466
		Sodium bicarbonate Cisplatin		3578
		Sodium bicarbonate : 50 mg/ml Cisplatin		4084
		Sodium bicarbonate : 84 mg/ml Cladribine : 0.015 mg/ml		1496

		Sodium bicarbonate : 84 mg/ml Cladribine : 0.5 mg/ml		1496
		Sodium bicarbonate Clindamycin phosphate		3526
		Sodium bicarbonate : 84 mg/ml Cloxacillin sodium : 100 mg/ml		3012
		Sodium bicarbonate Co-trimoxazole		3583
		Sodium bicarbonate : 14 mg/ml Cyclophosphamide : 20 mg/ml		150
		Sodium bicarbonate : 14 mg/ml Cytarabine : 0.6 mg/ml		150
		Sodium bicarbonate Dacarbazine		3605
		Sodium bicarbonate Dacarbazine		3267
		Sodium bicarbonate : 40 mg/ml Daptomycin : 5 mg/ml		3122
		Sodium bicarbonate : 14 mg/ml Daunorubicin hydrochloride : 0.52 mg/ml		150
		Sodium bicarbonate Daunorubicin/cytarabine liposomale : 0,4 mg/mL		4654
		Sodium bicarbonate : 84 mg/ml Dexmedetomidine : 4 µg/ml		1712
		Sodium bicarbonate : 84 mg/ml Diltiazem hydrochloride : 5 mg/ml		198
		Sodium bicarbonate : 84 mg/ml Diltiazem hydrochloride : 1 mg/ml		198
		Sodium bicarbonate Dimenhydrinate		2087
		Sodium bicarbonate : 84 mg/ml Dobutamine hydrochloride : 2 mg/ml		1041
		Sodium bicarbonate Dobutamine hydrochloride		3606
		Sodium bicarbonate : 50 mg/ml Dobutamine hydrochloride : 1 mg/ml		1058
		Sodium bicarbonate : 84 mg/ml Docetaxel : 0.9 mg/ml		1754
		Sodium bicarbonate Dopamine hydrochloride		3638
		Sodium bicarbonate : 84 mg/ml Doripenem : 5 mg/ml		2262
		Sodium bicarbonate Doxorubicin hydrochloride : 0.4 mg/ml		150
		Sodium bicarbonate : 14 mg/ml Doxorubicin hydrochloride : 0.4 mg/ml		150
		Sodium bicarbonate : 84 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
		Sodium bicarbonate Epinephrine hydrochloride		3086
		Sodium bicarbonate : 84 mg/ml Epinephrine hydrochloride : 1 & 10 µg/ml		2077



		Sodium bicarbonate Epirubicin hydrochloride		3632
		Sodium bicarbonate : 84 mg/ml Eravacycline : 0,6 mg/ml		4434
		Sodium bicarbonate Ertapenem : 10 & 20 mg/ml		1906
		Sodium bicarbonate Ertapenem : 10 & 20 mg/ml		1906
		Sodium bicarbonate : 84 mg/ml Esmolol hydrochloride : 10 mg/ml		3823
		Sodium bicarbonate Esmolol hydrochloride		3466
		Sodium bicarbonate Esmolol hydrochloride		3607
		Sodium bicarbonate : 14 mg/ml Etoposide : 0.6 mg/ml		150
		Sodium bicarbonate : 84 mg/ml Etoposide phosphate : 5 mg/ml		1410
		Sodium bicarbonate : 84 mg/ml Famotidine : 0.2 mg/ml		398
		Sodium bicarbonate : 84 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
		Sodium bicarbonate : 84 mg/ml Fentanyl citrate : 50 µg/ml		63
		Sodium bicarbonate : 84 mg/ml Filgrastim : 30 µg/ml		244
		Sodium bicarbonate : 84 mg/ml Flucloxacillin sodium : 20 mg/ml		1232
		Sodium bicarbonate : 84 mg/ml Fludarabine phosphate : 1 mg/ml		492
		Sodium bicarbonate : 14 mg/ml Folate calcium : 10 mg/ml		150
		Sodium bicarbonate : 84 mg/ml Fosfomycin : 30 mg/ml		4055
		Sodium bicarbonate : 84 mg/ml Furosemide : 10 mg/ml		3134
		Sodium bicarbonate : 84 mg/ml Furosemide : 10 mg/ml		3212
		Sodium bicarbonate : 84 mg/ml Furosemide : 1 mg/ml		1232
		Sodium bicarbonate Furosemide		3466
		Sodium bicarbonate Furosemide		3465
		Sodium bicarbonate : 84 mg/ml Furosemide : 10 mg/ml		3823
		Sodium bicarbonate : 84 mg/ml Furosemide : 10 mg/ml		3210
		Sodium bicarbonate : 84 mg/ml Gallium nitrate : 1 mg/ml		91
		Sodium bicarbonate : 84 mg/ml Gemcitabine hydrochloride : 16 >> 20 mg/ml		3262

		Sodium bicarbonate : 84 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
		Sodium bicarbonate : 40 mg/ml Gentamicin sulfate : 2,4 mg/ml		3122
		Sodium bicarbonate Gentamicin sulfate		3520
		Sodium bicarbonate Gentamicin sulfate		3643
		Sodium bicarbonate : 84 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
		Sodium bicarbonate : 28.056 mg/ml Granisetron hydrochloride : 1 mg/ml		57
		Sodium bicarbonate : 84 mg/ml Granisetron hydrochloride : 0,05 mg/ml		49
		Sodium bicarbonate : 84 mg/ml Haloperidol lactate : 0.5 mg/ml		3823
		Sodium bicarbonate : 84 mg/ml Haloperidol lactate : 0.5 mg/ml		3212
		Sodium bicarbonate Haloperidol lactate		3466
		Sodium bicarbonate Heparin sodium		3466
		Sodium bicarbonate : 84 mg/ml Heparin sodium : 500 UI/ml		3823
		Sodium bicarbonate : 84 mg/ml Heparin sodium : 500 UI/ml		3212
		Sodium bicarbonate : 14 mg/ml Heparin sodium : 500 UI/ml		150
		Sodium bicarbonate : 84 mg/ml Hetastarch : 60 mg/ml		1721
		Sodium bicarbonate Hydroxocobalamin		3932
		Sodium bicarbonate : 84 mg/ml Ibuprofen lysinate : 10 mg/ml		4419
		Sodium bicarbonate : 7.56 mg/ml Idarubicin hydrochloride : 1 mg/ml		491
		Sodium bicarbonate : 50 mg/ml Imipenem - cilastatin sodium : 250 & 500 mg/ml		21
		Sodium bicarbonate : 42 mg/ml Indomethacin sodium trihydrate : 1 mg/ml		467
		Sodium bicarbonate : 84 mg/ml Insulin : 2 UI/ml		3212
		Sodium bicarbonate Insulin		3466
		Sodium bicarbonate : 84 mg/ml Insulin : 2 UI/ml		3823
		Sodium bicarbonate : 84 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Sodium bicarbonate : 84 mg/ml Ketamine hydrochloride : 50 mg/ml		2109
		Sodium bicarbonate Labetalol hydrochloride		1380

		Sodium bicarbonate : 50 mg/ml Labetalol hydrochloride : 1,25 >> 3,75 mg/ml		1194
		Sodium bicarbonate Labetalol hydrochloride		3609
		Sodium bicarbonate : 84 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Sodium bicarbonate Levobupivacaine hydrochloride		3507
		Sodium bicarbonate : 42 mg/ml Levofloxacin : 5 mg/ml		1072
		Sodium bicarbonate : 40 mg/ml Linezolid : 1 mg/ml		3122
		Sodium bicarbonate : 84 mg/ml Linezolid : 2 mg/ml		1925
		Sodium bicarbonate Magnesium sulfate		3838
		Sodium bicarbonate : 37,39 mg/ml Mannitol : 25 mg/ml		298
		Sodium bicarbonate : 37,39 mg/ml Mannitol : 25 mg/ml		298
		Sodium bicarbonate : 3.75 mg/ml Mannitol : 25 mg/ml		322
		Sodium bicarbonate : 3.75 mg/ml Mannitol : 25 mg/ml		322
		Sodium bicarbonate : 3.75 mg/ml Mannitol : 25 mg/ml		322
		Sodium bicarbonate : 3.75 mg/ml Mannitol : 25 mg/ml		322
		Sodium bicarbonate : 84 mg/ml Melphalan : 0.1 mg/ml		169
		Sodium bicarbonate : 84 mg/ml Meropenem : 50 mg/ml		4319
		Sodium bicarbonate : 14 mg/ml Mesna : 1.8 mg/ml		150
		Sodium bicarbonate : 6.3 mg/ml Micafungin : 1.5 mg/ml		4057
		Sodium bicarbonate : 50 mg/ml Midazolam hydrochloride : 0.1 & 0.5 mg/ml		1888
		Sodium bicarbonate : 84 mg/ml Midazolam hydrochloride : 1 mg/ml		176
		Sodium bicarbonate : 14 mg/ml Midazolam hydrochloride : 5 mg/ml		150
		Sodium bicarbonate Midazolam hydrochloride		3466
		Sodium bicarbonate : 84 mg/ml Midazolam hydrochloride : 2.1 mg/ml		3823
		Sodium bicarbonate : 84 mg/ml Midazolam hydrochloride : 2.1 mg/ml		3212
		Sodium bicarbonate : 50 mg/ml Midazolam hydrochloride : 0.1 & 0.5 mg/ml		1888
		Sodium bicarbonate : 168 mg/ml Milrinone lactate : 0.8 mg/ml		813



		Sodium bicarbonate Moxifloxacin		3162
		Sodium bicarbonate : 42 & 84 mg/ml Moxifloxacin		3109
		Sodium bicarbonate : 84 mg/ml N-acetylcysteine : 200 mg/ml	∅	3766
		Sodium bicarbonate : 14 mg/ml Nalbuphine hydrochloride : 10 mg/ml	∅	150
		Sodium bicarbonate : 84 mg/ml Naloxone hydrochloride : 0.4 mg/ml	∅	3408
		Sodium bicarbonate : 50 mg/ml Nicardipine hydrochloride : 0,05 & 0,5 mg/ml	∅	44
		Sodium bicarbonate Nicardipine hydrochloride		3614
		Sodium bicarbonate Nicardipine hydrochloride		3941
		Sodium bicarbonate Nimodipine		3466
		Sodium bicarbonate : 84 mg/ml Nimodipine : 0.2 mg/ml	▲	3823
		Sodium bicarbonate : 84 mg/ml Nimodipine : 0.2 mg/ml	∅	3212
		Sodium bicarbonate : 84 mg/ml Nitroglycerin : 0.2 mg/ml	◆	3823
		Sodium bicarbonate Nitroglycerin		3466
		Sodium bicarbonate : 84 mg/ml Nitroglycerin : 0.2 mg/ml	∅	3212
		Sodium bicarbonate Norepinephrine bitartrate		642
		Sodium bicarbonate Ondansetron hydrochloride		3574
		Sodium bicarbonate : 8.4 mg/ml Ondansetron hydrochloride : 0.1 mg/ml	◆	1396
		Sodium bicarbonate : 14 mg/ml Ondansetron hydrochloride : 2 mg/ml	∅	150
		Sodium bicarbonate : 84 mg/ml Oritavancin : 0.8 >>2 mg/ml	◆	3152
		Sodium bicarbonate : 14 mg/ml Oxacillin sodium : 250 mg/ml	∅	150
		Sodium bicarbonate : 84 mg/ml Oxaliplatin : 0,5 mg/ml	◆	1662
		Sodium bicarbonate : 84 mg/ml Paclitaxel : 1.2 mg/ml	◆	248
		Sodium bicarbonate Pantoprazole sodium		2090
		Sodium bicarbonate : 0.084 mg/ml Paracetamol : 10 mg/ml		4742
		Sodium bicarbonate : 14 mg/ml Paracetamol : 200 mg/ml	∅	150
		Sodium bicarbonate : 84 mg/ml Pemetrexed disodium : 20 mg/ml	▲	1953

		Sodium bicarbonate Pethidine hydrochloride		3525
		Sodium bicarbonate Phenylephrine hydrochloride		3620
		Sodium bicarbonate Piperacillin sodium		3590
		Sodium bicarbonate : 84 mg/ml		301
		Sodium bicarbonate Oxaliplatin		3634
		Sodium bicarbonate : 42 mg/ml Pentoxifyllin : 5 mg/ml		4543
		Sodium bicarbonate Piperacillin sodium / tazobactam		3586
		Sodium bicarbonate : 84 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml		81
		Sodium bicarbonate : 84 mg/ml Plazomicin sulfate : 24 mg/ml		4145
		Sodium bicarbonate : 75 mg/ml Potassium chloride : 40 mEq/l		730
		Sodium bicarbonate : 75 mg/ml Potassium chloride : 40 mEq/l	RL	730
		Sodium bicarbonate : 84 mg/ml Potassium chloride : 10 mEq/l		3823
		Sodium bicarbonate : 84 mg/ml Potassium phosphate : 3 mmol/ml		4389
		Sodium bicarbonate : 84 mg/ml Propofol		660
		Sodium bicarbonate : 84 mg/ml Propofol : 10 mg/ml	∅	300
		Sodium bicarbonate : 50 mg/ml Rifampicin		3541
		Sodium bicarbonate : 84 mg/ml Salbutamol sulfate : 1 mg/ml	∅	3216
		Sodium bicarbonate : 84 mg/ml Sargramostim : 10 µg/ml		335
		Sodium bicarbonate : 84 mg/ml Sulbactam/durlobactam : 15/15 mg/ml		4801
		Sodium bicarbonate Suxamethonium chloride		3631
		Sodium bicarbonate Tacrolimus		3626
		Sodium bicarbonate : 84 mg/ml Tacrolimus : 1000 µg/ml		479
		Sodium bicarbonate : 84 mg/ml Tedizolid phosphate : 0.8 mg/ml		3827
		Sodium bicarbonate : 84 mg/ml Telavancin hydrochloride : 7.5 mg/ml		3254
		Sodium bicarbonate : 84 mg/ml Telavancin hydrochloride : 7.5 mg/ml	RL	3254
		Sodium bicarbonate Temocilline		2296

		Sodium bicarbonate : 84 mg/ml Teniposide : 0.1 mg/ml		905
		Sodium bicarbonate : 84 mg/ml Thiopental sodium : 25 mg/ml		3767
		Sodium bicarbonate : 84 mg/ml Thiopental sodium : 60 mg/ml		3212
		Sodium bicarbonate : 84 mg/ml Thiopental sodium : 60 mg/ml		3823
		Sodium bicarbonate Thiopental sodium		3466
		Sodium bicarbonate : 84 mg/ml Thiotepa : 1 mg/ml		249
		Sodium bicarbonate Ticarcillin / clavulanic acid		3587
		Sodium bicarbonate : 40 mg/ml Tobramycin sulfate : 2,4 mg/ml		3122
		Sodium bicarbonate Urapidil		4065
		Sodium bicarbonate : 84 mg/ml Urapidil : 5 mg/ml		3823
		Sodium bicarbonate : 84 mg/ml Urapidil : 5 mg/ml		3212
		Sodium bicarbonate Urapidil		3466
		Sodium bicarbonate : 40 mg/ml Vancomycin hydrochloride : 10 mg/ml		3122
		Sodium bicarbonate : 40 mg/ml Vancomycin hydrochloride : 5 mg/ml		3122
		Sodium bicarbonate : 12.6 mg/ml Vasopressin : 0.2 UI/ml		2017
		Sodium bicarbonate : 7.49 mg/ml Verapamil hydrochloride : 0.08 mg/ml	 	1057
		Sodium bicarbonate : 14 mg/ml Vincristine sulfate : 0.1 mg/ml		150
		Sodium bicarbonate : 84 mg/ml Vinorelbine tartrate : 1 mg/ml		84
		Sodium bicarbonate : 42 mg/ml Voriconazole		3566
		Sodium bicarbonate : 1 mg/ml	RL	4603
		Sodium bicarbonate Verapamil hydrochloride		1100
		Sodium bicarbonate : 84 mg/ml		1415
		Sodium bicarbonate : 14 mg/ml Vindesine sulfate : 0.1 mg/ml		150



Bibliographie

	Type	Source
3	Revue	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
14	Revue	Gilbert DL, Trissel LA, Martinez JF. Compatibility of ciprofloxacin lactate with sodium bicarbonate during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1193-1195.
21	Revue	Bigley FP, Forsyth RJ, Henley MW. Compatibility of imipenem-cilastatin sodium with commonly used intravenous solutions. Am J Hosp Pharm 1986 ; 43: 2803-2809.
44	Revue	Baaske DM, DeMay JF, Latona CA, Mirmira S, Sigvardson KW. Stability of nicardipine hydrochloride in intravenous solutions. Am J Health-Syst Pharm 1996 ; 53: 1701-1705.
49	Revue	Trissel LA, Martinez JF. Compatibility of granisetron hydrochloride with selected alkaline drugs. Am J Health-Syst Pharm 1995 ; 52: 208.
57	Revue	Mayron D, Gennaro AR. Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs. Am J Health-Syst Pharm 1996 ; 53: 294-304.
63	Revue	Marquardt Ed, Lam SSY. Visual compatibility of fentanyl citrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 811-812.
81	Revue	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Revue	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
91	Revue	Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210.
93	Revue	Hutchings SR, Rusho WJ, Tyler LS. Compatibility of cefmetazole sodium with commonly used drugs during Y-site delivery. Am J Health-Syst Pharm 1996 ; 53: 2185-2188.
99	Revue	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
150	Revue	Aujoulat P, Coze C, Braguer D, Raybaud C. Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens. J Pharm Clin 1993 ; 12: 31-35.

169	Revue	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
176	Revue	Mantong ML, Marquardt ED. Visual compatibility of midazolam hydrochloride with selected drugs during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 2567-2568.
182	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
198	Revue	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
200	Revue	Korth-Bradley JM, Ludwig S, Callaghan C. Incompatibility of amiodarone hydrochloride and sodium bicarbonate injections. Am J Health-Syst Pharm 1995 ; 52: 2340.
205	Revue	Strozyk WR, Williamson R, Thompson D. Incompatibility of amiodarone hydrochloride and evacuated glass bottles. Am J Health-Syst Pharm 1996 ; 53: 184.
244	Revue	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
248	Revue	Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 300-304.
249	Revue	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
269	Revue	Trissel LA. Concentration-dependent precipitation of sodium bicarbonate with ciprofloxacin lactate. Am J Health-Syst Pharm 1996 ; 53: 84-85.
285	Revue	Elmore RL, Contois ME, Kelly J, Noe A, Poirier A. Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs. Clin Ther 1996 ; 18: 246-255.
288	Revue	Cervenka P, Dejong DJ, Butler BL, Monzingo MD. Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-site administration. Hosp Pharm 1992 ; 27: 957-958,961-962.
289	Revue	Jim LK. Physical and chemical compatibility of intravenous ciprofloxacin with other drugs. Ann Pharmacotherapy 1993 ; 27: 704-707.
298	Revue	Matuschka PR, Smith WR, Vissing RS. Compatibility of mannitol and sodium bicarbonate in injectable fluids. Am J Health-Syst Pharm 1995 ; 52: 320-321.
299	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.



301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Revue	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
322	Revue	Matuschka PR, Hill LJ. More on compatibility of mannitol and sodium bicarbonate in injectable fluids. Am J Health-Syst Pharm 1996 ; 53: 2639.
335	Revue	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
336	Revue	Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409.
398	Revue	Jay GT, Fanikos J, Souney PF. Visual compatibility of famotidine with commonly used critical-care medications during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1556-1557.
467	Revue	Ishisaka DY, van Vleet J, Marquardt E. Visual compatibility of indomethacin sodium trihydrate with drugs given to neonates by continuous infusion. Am J Hosp Pharm 1991 ; 48: 2442-2443.
479	Revue	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
491	Revue	Turowski RC, Durthaler JM. Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2181-2184.
492	Revue	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
642	Revue	Baumgartner TG, Knudsen AK, Dunn AJ, Kilroy RA. Norepinephrine stability in saline solutions. Hosp Pharm 1988 ; 23: 44,49, 59.
660	Revue	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
715	Revue	Colvin M, Hartner J, Summerfield M. Stability of carmustine in the presence of sodium bicarbonate. Am J Hosp Pharm 1980 ; 37: 677-678.
730	Revue	Allen LV, Saul Levinson R, Phisutsinthop D. Compatibility of various admixtures with secondary additives at Y-injection site of intravenous administration sets. Am J Hosp Pharm 1977 ; 34: 939-943.
813	Revue	Akkermann SR, Zhang H, Mullins RE, Yaughn K. Stability of milrinone lactate in the presence of 29 critical care drugs and 4 IV solutions. Am J Health-Syst Pharm 1999 ; 56: 63-68.
850	Revue	Munson J, Kubiak EJ, Cohon MS. Cytosine arabinose stability in intravenous admixtures with sodium bicarbonate and in plastic syringes. Drug Intell Clin Pharm 1982 ; 16: 765-767.

905	Revue	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1041	Revue	Hasegawa GR, Eder JF. Visual compatibility of dobutamine hydrochloride with other injectable drugs. Am J Hosp Pharm 1984 ; 41: 949-951.
1057	Revue	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.
1058	Revue	Kirschenbaum HL, Aronoff W, Piltz GW, Perentesis GP, Cutie AJ. Compatibility and stability of dobutamine hydrochloride with large-volume parenterals and selected additives. Am J Hosp Pharm 1983 ; 40: 1690-1691.
1072	Revue	Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA. Compatibility of levofloxacin with 34 medications during simulated Y-site administration. Am J Health-Syst Pharm 1999 ; 56: 1458-1459.
1100	Revue	Bar-Or D, Kulig K, Marx JA, Rosen P. Precipitation of verapamil. Ann Intern Med 1982 ; 97: 619.
1194	Revue	Yuen PHC, Taddei CR, Wyka BE, Chaudry IA. Compatibility and stability of labetalol hydrochloride in commonly used intravenous solutions. Am J Hosp Pharm 1983 ; 40: 1007-1009.
1232	Revue	Beatson C, Taylor A. A physical compatibility study of furosemide & flucloxacillin injections. Br J Pharm Pract 1987 ; 9: 223-226, 236.
1380	Revue	Alam AS. Identification of labetalol precipitate. Am J Hosp Pharm 1984 ; 41: 74.
1396	Revue	Hauser AR, Trissel LA, Martinez JF. Ondansetron compatible with sodium acetate. J Clin Oncol 1993 ; 11: 197.
1410	Revue	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1496	Revue	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1611	Revue	Chalmers JR, Bobek MB, Militello MA. Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs. Am J Health-Syst Pharm 2001 ; 58: 504-506.
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.

1662	Revue	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1712	Revue	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Revue	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Revue	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1754	Revue	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1803	Revue	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1888	Revue	Janknegt R, Van den Berg TJ, De Jong M, Oldenhof HGJ, Steenhoek A. Compatibility study of midazolam. Ziekenhuisfarmacie 1986 ; 2: 45-48.
1906	Revue	McQuade MS, Van Nostrand V, Shariter J, Kanike JD, Forsyth RJ. Stability and compatibility of reconstituted ertapenem with commonly used iv infusion and coinfusion solutions. Am J Health-Syst Pharm 2004 ; 61: 38-45.
1925	Revue	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	Revue	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982	Revue	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2017	Revue	Barker B, Feddema S, Rusho WJ, Dengg R. Visual compatibility of vasopressin with other injectable drugs. Am J Health-Syst Pharm 2005 ; 62: 1969-1976.
2077	Revue	Bonhomme L, Benhamou D, Comoy E, Preaux N. Stability of epinephrine in alkalized solutions. Ann Emerg Med 1990 ; 19: 1242-1244.
2087	Revue	Ferreira E, Forest JM, Hildgen P. Compatibility of dimenhydrinate injectable by Y administration. Pharmactuel 2004 ; 37: 17-20.
2090	Revue	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2109	Revue	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l'administration en dérivé avec d'autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2262	Revue	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administration Am J Health-Syst Pharm 2008 ; 65: 1261-1265.

2269	Revue	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2296	Laboratoire	Témocilline (Negaban®) - Résumé des caractéristiques du produit Eumedica 2017
2737	Revue	Batty KT, Ilett KF, Timothy Davis ME. Chemical stability of artesunate injection and proposal for its administration by intravenous infusion. J Pharm Pharmacol 1996 ; 48, 1: 22-26.
2878	Revue	Pascuet E, Donnelly RF, Garceau D, Vaillancourt R. Buffered Lidocaine Hydrochloride Solution With and Without Epinephrine: Stability in Polypropylene Syringes. Can J Hosp Pharm 2009 ; 62, 5: 375-380.
3012	Revue	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3076	Revue	François JH, Hecq JD, Vanbeckbergen D, Jamart J, Galanti L. Effect of freezing, long-term storage and microwave thawing on the stability of a mixture of diclofenac and sodium bicarbonate in glucose 5% polyolefin bags. Ann Pharm Fr 2009 ; 67: 427-432.
3084	Laboratoire	Ixabepilone (Ixempra®) – Summary of Product Characteristics Bristol Myers Squibb 2009
3086	Revue	Robinson, J, Fernando, R, Sun Wai, W.Y., Reynolds, F. Chemical stability of bupivacaine, lidocaine and epinephrine in pH-adjusted solutions. Anaesthesia 2000 ; 55, 9: 853-858.
3109	Laboratoire	Moxifloxacin (Izilox®) -Notice information Bayer Schering Pharma 2010
3116	Revue	Wear J, McPherson TB, Kolling WM. Stability of sodium bicarbonate solutions in polyolefin bags. Am J Health-Syst Pharm 2010 ;67: 1026-1029.
3122	Revue	Dotson B, Lynn S, Savakis K, Churchwell MD. Physical compatibility of 4% sodium citrate with selected antimicrobial agents. Am J Health-Syst Pharm 2010 ; 67: 1195-1198.
3134	Revue	Perez Jua En, Maqueda Palau M, Arévalo Rubert Mt, Ribas Nicolau B, Amoros Cerdà SM. Compatibilidad visual y física de la furosemida en mezclas intravenosas para perfusión continua. Enferm Intensiva 2010 ; 21: 96-103.
3152	Revue	Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3162	Laboratoire	Moxifloxacin (Izilox®) - Résumé des caractéristiques du produits Bayer HealthCare 2010
3210	Revue	Jasti Bhaskara R, Saraf Poonam. Compatibility of Parenteral Furosemide with Seventeen Secondary Drugs Used in Standard Concentrations. Int J Pharm Compound 2011 ; 15, 3: 259-261.
3212	Revue	Ribas Nicolau, B.; P?rez Juan, E.; Amor?s Cerd?, S.M.; Ar?valo Rubert, M.J.; Maqueda Palau, M. Compatibilidad física del bicarbonato sódico con fármacos de uso frecuente en la unidad de cuidados intensivos. Enferm Intensiva 2011 ;22:78-82.
3216	Revue	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3249	Revue	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.

3254	Revue	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3262	Revue	Manners S, Galettis P, de Souza P. Conditions causing gemcitabine crystallization. J Oncol Pharm Practice 2011 ; 17, 4: 395-399.
3263	Revue	Donnelly R.F. Stability of buffered lidocaine in glass vials. Can J Hosp Pharm 2011 ; 64, 4: 289-290.
3267	Laboratoire	Lipomed Laboratories Dacarbazine Lipomed - Summary of Product Characteristics Lipomed 2011
3329	Revue	Sayre B.E, Prettyman T, Kaushal G. Extended Stability of Sodium Bicarbonate Infusions Prepared in Polyolefin Bags. Hosp Pharm 2012 ; 47, 7: 538-543.
3379	Revue	Fox L.M, Wilder A.G, Foushee J.A. Physical compatibility of various drugs with neonatal total parenteral nutrient solution during simulated Y-site administration. Am J Health-Syst Pharm 2013 ;70:520-524.
3408	Revue	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3464	Revue	Monica Maqueda-Palau, Eva Pérez-Juan, Maria Josep Arévalo-Rubert, Sylvia Monica Amoros-Cerda, Bàrbara Ribas-Nicolau. Compatibilidad física de la amiodarona en perfusión continua Enferm Clin 2011 21:25-29.
3465	Revue	E. Pérez Juan, M. Maqueda Palau, M. Arévalo Rubert, B. Ribas Nicolau, S.M. Amorós Cerdá. Compatibilidad visual y física de la furosemida en mezclas intravenosas para perfusión continua. Enferm Intensiva 2010 ;21:96-103.
3466	Revue	B. Ribas Nicolau, E. Pérez Juan, S.M. Amorós Cerdá, M.J. Arévalo Rubert, M. Maqueda Palau. Compatibilidad física del bicarbonato sódico con fármacos de uso frecuente en la unidad de cuidados intensivos Enferm Intensiva 2011 ;22:78-82.
3507	Laboratoire	Chirocaine - Summary of Product Characteristics AbbVie 2013
3520	Laboratoire	Cidomycin - Summary of product Characteristics. Sanofi 2011
3525	Laboratoire	Pethidine hydrochloride - Summary of product Characteristics AMCO Amdipharm Mercury 2012
3526	Laboratoire	Clindamycin (Dalacin®) - Summary of Product Characteristics Farmacia 2010
3541	Laboratoire	Rifampicin (Rifadin®) – Summary of Product Characteristics Sanofi 2011
3543	Laboratoire	Ceftazidime – Summary of Product Characteristics Woekhardt 2013
3545	Laboratoire	Amoxicilline / acide clavulanique - Résumé des caractéristiques du produit Mylan SAS 2009
3566	Laboratoire	Voriconazole (Vfend®) - Summary of Product characteristics. Pfizer 2013
3574	Laboratoire	Ondansetron - Résumé des caractéristiques du produit Accord Healthcare France SAS 2013
3578	Laboratoire	Cisplatin - Summary of Product Characteristics Accord Healthcare 2011




3583	Laboratoire	Sulfaméthoxazole triméthoprime (Bactrim®) - Résumé des caractéristiques du produit Roche 2013
3586	Laboratoire	Piperacilline tazobactam Actavis® - Résumé des caractéristiques du produit Actavis France 2010
3587	Laboratoire	Ticarilline/acide clavulanique (Timentin®) - Summary of Product Characteristics GlaxoSmithKline 2014
3590	Laboratoire	Piperacilline - Résumé des caractéristiques du produit Dakota Pharm 2011
3601	Laboratoire	Cisatracurium Actavis - Résumé des Caractéristiques du Produit Actavis 2012
3605	Laboratoire	Dacarbazine (Dacarbazine Lipomed®) - Résumé des caractéristiques du produit Lipomed 2010
3606	Laboratoire	Dobutamine - Summary of Product Characteristics Wokhardt 2013
3607	Laboratoire	Esmolol hydrochloride for injection - Summary of Product Characteristics AOP Orphan Pharmaceuticals AG 2013
3609	Laboratoire	Labetalol (Trandate®) - Summary of Product Characteristics Aspen Pharma 2013
3614	Laboratoire	Nicardipine Injection - Summary of Product Characteristics American Regent Inc 2013
3620	Laboratoire	Phenylephrine - Summary of Product Characteristics Beacon Pharmaceuticals 2012
3626	Laboratoire	Tacrolimus (Prograf®) - Résumé des Caractéristiques du Produit Astellas Pharma 2014
3629	Laboratoire	Atracurium (Atracurium solution for injection/infusion®) - Summary of Product Characteristics Actavis UK 2014
3631	Laboratoire	Suxamethonium (Suxamethonium Aguetant®) - Résumé des caractéristiques du produit Aguettant 2016
3632	Laboratoire	Epirubicine (Epirubicine Hospira®) - Summary of Product Characteristics Hospira 2017
3634	Laboratoire	Oxaliplatine (Oxaliplatine Accord®) - Résumé des caractéristiques du produit Accord Healthcare 2011
3638	Laboratoire	Dopamin (Dopamine 40 mg/mL sterile concentrate®) - Summary of Product Characteristics Hospira 2010
3643	Laboratoire	Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics Sanofi 2015
3644	Laboratoire	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3676	Laboratoire	Atracurium bésilate (Atracurium Hospira®) - Résumé des caractéristiques du produit Hospira 2014
3766	Revue	Forrest J.M, Hildgen P. Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3767	Revue	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3823	Revue	Juan E.P, Palau M.M, Cerdá S.A, Rubert M.A, Nicolau B.R. Compatibilité physique de médicaments administrés dans l'unité de soins intensifs  Pharmactuel 2015 ; 48, 3 : 146-152.


3824	Revue	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3838	Laboratoire	Magnesium Sulphate - Summary of Product Characteristics Martindale Pharmaceuticals Ltd 2007
3883	Laboratoire	Ceftazidime - Résumé des caractéristiques du produit Arrow 2016
3932	Laboratoire	Hydroxocobalamine (Cyanokit®) - Résumé des caractéristiques du produit Serb Laboratoire 2015
3941	Laboratoire	Nicardipine - Summary of Product Characteristics Concordia International 2017
3964	Revue	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
4055	Revue	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4057	Revue	Joiner L, Ynes C, Arnold J, Miller R, Gorman G. Physical Compatibility of Micafungin With Sodium Bicarbonate Hydratation Fluids Commonly Used With High-Dose Methotrexate Chemotherapy. Hosp Pharm 2018 ; 53, 2: 125-127.
4065	Laboratoire	Urapidil (Eupressyl® - résumé des caractéristiques du produit) Mylan 2018
4084	Laboratoire	Cisplatine - Résumé des caractéristiques du produits Accord Health Care 2017
4145	Revue	Asempta T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4319	Revue	Lessard J-J, Caron E, Schérier H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4383	Revue	Naorungroj T, Neto AS, Fujii T, Jude B, Udy A, Bellomo R. Stability of bicarbonate in normal saline: a technical report. Crit Care Resusc 2020 ;22(1):83-85.
4389	Revue	Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosiimendan et la kétamine. Pharmactuel 2019 ;52,4:206-213
4419	Revue	Holt R.J, Siegert S.W.K, Krishna A. Physical Compatibility of Ibuprofen Lysine Injection with Selected Drugs During Simulated Y-site Injection. J Pediatr Pharmacol Ther 2008 ; 13, 3: 155-161.

4434	Revue	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4528	Revue	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4543	Revue	Senarathna G, Strunk T, Petrovski M, Batty K. Physical compatibility of pentoxifylline and intravenous medications. Archives of Disease in Childhood 2018 ;104:292–295.
4603	Revue	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4654	Poster	Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R. Compatibilité visuelle du Vyxeos® lors d’administration en Y avec une sélection de médicaments injectables. Communication personnelle 2021
4742	Revue	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4801	Revue	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:






# Stabilis



Sodium bicarbonate



## Compatibilités

			
	Sodium bicarbonate Salbutamol sulfate		549



## Bibliographie

	Type	Source
549	Revue	Owsley HD, Rusho WJ. Compatibility of common respiratory therapy drug combinations. Int J Pharm Compound 1997 ; 1: 121-122.



# Dictionnaire

	électrolyte		Injectable
	Noms commerciaux		Stabilité des solutions
	Contenant		Molécule
	Concentration		Température
	Conservation		Durée de stabilité
	Biosimilaire		Données conflictuelles
	Bibliographie		Polyoléfine
	Eau pour préparation injectable		Lumière
	Heure		Non précisée
	Jour		Chlorure de sodium 0,9%
	Glucose 5%		A l'abri de la lumière
	Stabilité en mélange		Solvant
	Molécule		Verre
	Aucun		Polyvinyl chlorure
	Polyéthylène		Polypropylène
	Non précisé		Avec ou sans lumière
	Facteur influençant la stabilité		NaHCO3
	Provoque		Dégradation
	Compatibilités		Compatible
	Précipitation en 1 heure		Incompatible
	Incompatibilité non précisée		Précipitation immédiate
	Turbidité en 1 heure		Turbidité immédiate
	Nutrition parentérale (mélange binaire)		Instabilité chimique
	NaCl 0,9% ou glucose 5%	<b>RL</b>	Ringer lactate
	Précipitation en 24 heures		Précipitation en 15 minutes
	Turbidité en 2 heures		NaCl 0,9% + bactériostatique
	Précipitation en 6 heures		Précipitation en 4 heures
	Perte de turbidité		Précipitation en 30 minutes
	Dégagement gazeux		Solvant spécifique
	Turbidité en 15 minutes		NaCl 0,45% Glucose 5%



	Chlorure de sodium 0,45%		Glucose 10%
	Turbidité à 24 heures		Précipitation en 2 heures
	Instabilité de l'émulsion à 6 heures		Nutrition parentérale (mélange ternaire)
	Voie d'administration		Intraveineuse
	Perfusion continue		Bibliographie
	Aérosol		Dictionnaire